{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:14:51Z","timestamp":1790788491236,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T00:00:00Z","timestamp":1561507200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T00:00:00Z","timestamp":1561507200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson\u2019s Research","doi-asserted-by":"publisher","award":["12062"],"award-info":[{"award-number":["12062"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011199","name":"FP7 Ideas: European Research Council","doi-asserted-by":"publisher","award":["Inmind"],"award-info":[{"award-number":["Inmind"]}],"id":[{"id":"10.13039\/100011199","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s00259-019-04369-6","type":"journal-article","created":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T07:06:06Z","timestamp":1561532766000},"page":"2051-2064","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["[11C]JNJ54173717, a novel P2X7 receptor radioligand as marker for neuroinflammation: human biodistribution, dosimetry, brain kinetic modelling and quantification of brain P2X7 receptors in patients with Parkinson\u2019s disease and healthy volunteers"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6646-106X","authenticated-orcid":false,"given":"Donatienne","family":"Van Weehaeghe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Koole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Deman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas H.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Souche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Serdons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Sunaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Bormans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Vandenberghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Van Laere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,26]]},"reference":[{"key":"4369_CR1","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3389\/fncel.2018.00072","volume":"12","author":"SD Skaper","year":"2018","unstructured":"Skaper SD, Facci L, Zusso M, Giusti P. An inflammation-centric view of neurological disease: beyond the neuron. Front Cell Neurosci. 2018;12:72.","journal-title":"Front Cell Neurosci"},{"issue":"2","key":"4369_CR2","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.1476-5381.2010.01025.x","volume":"162","author":"SL Able","year":"2011","unstructured":"Able SL, Fish RL, Bye H, Booth L, Logan YR, Nathaniel C, et al. Receptor localization, native tissue binding and ex vivo occupancy for centrally penetrant P2X7 antagonists in the rat. Br J Pharmacol. 2011;162(2):405\u201314.","journal-title":"Br J Pharmacol"},{"issue":"10","key":"4369_CR3","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1002\/glia.23001","volume":"64","author":"A Bhattacharya","year":"2016","unstructured":"Bhattacharya A, Biber K. The microglial ATP-gated ion channel P2X7 as a CNS drug target. Glia. 2016;64(10):1772\u201387.","journal-title":"Glia"},{"issue":"1","key":"4369_CR4","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/glia.22904","volume":"64","author":"A Masuch","year":"2016","unstructured":"Masuch A, Shieh CH, van Rooijen N, van Calker D, Biber K. Mechanism of microglia neuroprotection: involvement of P2X7, TNFalpha, and valproic acid. Glia. 2016;64(1):76\u201389.","journal-title":"Glia"},{"issue":"11","key":"4369_CR5","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/j.biocel.2010.06.021","volume":"42","author":"M Monif","year":"2010","unstructured":"Monif M, Burnstock G, Williams DA. Microglia: proliferation and activation driven by the P2X7 receptor. Int J Biochem Cell Biol. 2010;42(11):1753\u20136.","journal-title":"Int J Biochem Cell Biol"},{"key":"4369_CR6","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.neuroscience.2014.08.036","volume":"279","author":"X Chen","year":"2014","unstructured":"Chen X, Hu J, Jiang L, Xu S, Zheng B, Wang C, et al. Brilliant blue G improves cognition in an animal model of Alzheimer\u2019s disease and inhibits amyloid-beta-induced loss of filopodia and dendrite spines in hippocampal neurons. Neuroscience. 2014;279:94\u2013101.","journal-title":"Neuroscience"},{"issue":"8","key":"4369_CR7","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1016\/j.neurobiolaging.2011.09.040","volume":"33","author":"JI Diaz-Hernandez","year":"2012","unstructured":"Diaz-Hernandez JI, Gomez-Villafuertes R, Leon-Otegui M, Hontecillas-Prieto L, Del Puerto A, Trejo JL, et al. In vivo P2X7 inhibition reduces amyloid plaques in Alzheimer\u2019s disease through GSK3beta and secretases. Neurobiol Aging. 2012;33(8):1816\u201328.","journal-title":"Neurobiol Aging"},{"issue":"4","key":"4369_CR8","doi-asserted-by":"publisher","first-page":"669","DOI":"10.3727\/096368917X695227","volume":"26","author":"EG Ferrazoli","year":"2017","unstructured":"Ferrazoli EG, de Souza HD, Nascimento IC, Oliveira-Giacomelli A, Schwindt TT, Britto LR, et al. Brilliant blue G, but not fenofibrate, treatment reverts hemiparkinsonian behavior and restores dopamine levels in an animal model of Parkinson\u2019s disease. Cell Transplant. 2017;26(4):669\u201377.","journal-title":"Cell Transplant"},{"issue":"2","key":"4369_CR9","doi-asserted-by":"publisher","first-page":"768","DOI":"10.3892\/mmr.2016.6070","volume":"15","author":"XH Wang","year":"2017","unstructured":"Wang XH, Xie X, Luo XG, Shang H, He ZY. Inhibiting purinergic P2X7 receptors with the antagonist brilliant blue G is neuroprotective in an intranigral lipopolysaccharide animal model of Parkinson\u2019s disease. Mol Med Rep. 2017;15(2):768\u201376.","journal-title":"Mol Med Rep"},{"issue":"5","key":"4369_CR10","doi-asserted-by":"publisher","first-page":"749","DOI":"10.4103\/1673-5374.206643","volume":"12","author":"R Sluyter","year":"2017","unstructured":"Sluyter R, Bartlett R, Ly D, Yerbury JJ. P2X7 receptor antagonism in amyotrophic lateral sclerosis. Neural Regen Res. 2017;12(5):749\u201350.","journal-title":"Neural Regen Res"},{"key":"4369_CR11","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1750-1326-6-28","volume":"6","author":"Z Hracsko","year":"2011","unstructured":"Hracsko Z, Baranyi M, Csolle C, Goloncser F, Madarasz E, Kittel A, et al. Lack of neuroprotection in the absence of P2X7 receptors in toxin-induced animal models of Parkinson\u2019s disease. Mol Neurodegener. 2011;6:28.","journal-title":"Mol Neurodegener"},{"issue":"20","key":"4369_CR12","doi-asserted-by":"publisher","first-page":"4102","DOI":"10.1093\/hmg\/ddt259","volume":"22","author":"S Apolloni","year":"2013","unstructured":"Apolloni S, Amadio S, Montilli C, Volonte C, D\u2019Ambrosi N. Ablation of P2X7 receptor exacerbates gliosis and motoneuron death in the SOD1-G93A mouse model of amyotrophic lateral sclerosis. Hum Mol Genet. 2013;22(20):4102\u201316.","journal-title":"Hum Mol Genet"},{"key":"4369_CR13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1471-2377-6-12","volume":"6","author":"Y Yiangou","year":"2006","unstructured":"Yiangou Y, Facer P, Durrenberger P, Chessell IP, Naylor A, Bountra C, et al. COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells\/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol. 2006;6:12.","journal-title":"BMC Neurol"},{"issue":"9","key":"4369_CR14","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.2967\/jnumed.115.169995","volume":"57","author":"D Ory","year":"2016","unstructured":"Ory D, Celen S, Gijsbers R, Van Den Haute C, Postnov A, Koole M, et al. Preclinical evaluation of a P2X7 receptor-selective radiotracer: PET studies in a rat model with local overexpression of the human P2X7 receptor and in nonhuman primates. J Nucl Med. 2016;57(9):1436\u201341.","journal-title":"J Nucl Med"},{"issue":"2","key":"4369_CR15","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s11302-009-9136-4","volume":"5","author":"SJ Fuller","year":"2009","unstructured":"Fuller SJ, Stokes L, Skarratt KK, Gu BJ, Wiley JS. Genetics of the P2X7 receptor and human disease. Purinergic Signal. 2009;5(2):257\u201362.","journal-title":"Purinergic Signal"},{"issue":"15","key":"4369_CR16","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/mds.23429","volume":"25","author":"CL Tomlinson","year":"2010","unstructured":"Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson\u2019s disease. Mov Disord. 2010;25(15):2649\u201353.","journal-title":"Mov Disord"},{"issue":"6","key":"4369_CR17","first-page":"1023","volume":"46","author":"MG Stabin","year":"2005","unstructured":"Stabin MG, Sparks RB, Crowe E. OLINDA\/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46(6):1023\u20137.","journal-title":"J Nucl Med"},{"issue":"11","key":"4369_CR18","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/BF00175858","volume":"19","author":"L Johansson","year":"1992","unstructured":"Johansson L, Mattsson S, Nosslin B, Leide-Svegborn S. Effective dose from radiopharmaceuticals. Eur J Nucl Med. 1992;19(11):933\u20138.","journal-title":"Eur J Nucl Med"},{"key":"4369_CR19","doi-asserted-by":"crossref","unstructured":"Schramm G, Koole M, Willekens SMA, Rezaei A, Van Weehaeghe D, Delso G, et al. Regional accuracy of ZTE-based attenuation correction in static and dynamic brain PET\/MR. Med Phys. 2018. arXiv:1806.03481.","DOI":"10.3389\/fphy.2019.00211"},{"key":"4369_CR20","doi-asserted-by":"publisher","unstructured":"Koole M, Schmidt M, Hijzen A, Ravenstijn P, Vandermeulen C, Van Weehaeghe D, et al. (18)F-JNJ-64413739, a novel PET ligand for the P2X7 ion channel: radiation dosimetry, kinetic modeling, test-retest variability and occupancy of the P2X7 antagonist JNJ-54175446. J Nucl Med. 2019;60(5):683\u201390. \n                    https:\/\/doi.org\/10.2967\/jnumed.118.216747\n                    \n                  .","DOI":"10.2967\/jnumed.118.216747"},{"issue":"2","key":"4369_CR21","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1373\/clinchem.2016.263897","volume":"63","author":"K Neveling","year":"2017","unstructured":"Neveling K, Mensenkamp AR, Derks R, Kwint M, Ouchene H, Steehouwer M, et al. BRCA testing by single-molecule molecular inversion probes. Clin Chem. 2017;63(2):503\u201312.","journal-title":"Clin Chem"},{"issue":"3","key":"4369_CR22","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1007\/s00259-011-2005-8","volume":"39","author":"P Zanotti-Fregonara","year":"2012","unstructured":"Zanotti-Fregonara P, Innis RB. Suggested pathway to assess radiation safety of 11C-labeled PET tracers for first-in-human studies. Eur J Nucl Med Mol Imaging. 2012;39(3):544\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4369_CR23","doi-asserted-by":"publisher","unstructured":"Berdyyeva T, Xia C, Taylor N, He Y, Chen G, Huang C, et al. PET imaging of the P2X7 ion channel with a novel tracer [18F]JNJ-64413739 in a rat model of neuroinflammation. Mol Imaging Biol. 2019. \n                    https:\/\/doi.org\/10.1007\/s11307-018-01313-2\n                    \n                  .","DOI":"10.1007\/s11307-018-01313-2"},{"issue":"1","key":"4369_CR24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13550-017-0275-2","volume":"7","author":"ER Fantoni","year":"2017","unstructured":"Fantoni ER, Dal Ben D, Falzoni S, Di Virgilio F, Lovestone S, Gee A. Design, synthesis and evaluation in an LPS rodent model of neuroinflammation of a novel 18F-labelled PET tracer targeting P2X7. EJNMMI Res. 2017;7(1):31.","journal-title":"EJNMMI Res"},{"key":"4369_CR25","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.apradiso.2018.11.006","volume":"144","author":"M Gao","year":"2018","unstructured":"Gao M, Wang M, Glick-Wilson BE, Meyer JA, Peters JS, Territo PR, et al. Synthesis and initial in vitro characterization of a new P2X7R radioligand [18F]IUR-1602. Appl Radiat Isot. 2018;144:10\u20138.","journal-title":"Appl Radiat Isot"},{"issue":"5","key":"4369_CR26","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1097\/MNM.0000000000000660","volume":"38","author":"J Han","year":"2017","unstructured":"Han J, Liu H, Liu C, Jin H, Perlmutter JS, Egan TM, et al. Pharmacologic characterizations of a P2X7 receptor-specific radioligand, [11C]GSK1482160 for neuroinflammatory response. Nucl Med Commun. 2017;38(5):372\u201382.","journal-title":"Nucl Med Commun"},{"issue":"8","key":"4369_CR27","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/jlcr.3206","volume":"57","author":"B Janssen","year":"2014","unstructured":"Janssen B, Vugts DJ, Funke U, Spaans A, Schuit RC, Kooijman E, et al. Synthesis and initial preclinical evaluation of the P2X7 receptor antagonist [11C]A-740003 as a novel tracer of neuroinflammation. J Label Compd Radiopharm. 2014;57(8):509\u201316.","journal-title":"J Label Compd Radiopharm"},{"issue":"1","key":"4369_CR28","doi-asserted-by":"publisher","first-page":"6580","DOI":"10.1038\/s41598-018-24814-0","volume":"8","author":"B Janssen","year":"2018","unstructured":"Janssen B, Vugts DJ, Wilkinson SM, Ory D, Chalon S, Hoozemans JJM, et al. Identification of the allosteric P2X7 receptor antagonist [11C]SMW139 as a PET tracer of microglial activation. Sci Rep. 2018;8(1):6580.","journal-title":"Sci Rep"},{"issue":"9","key":"4369_CR29","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/j.bmcl.2018.03.044","volume":"28","author":"M Gao","year":"2018","unstructured":"Gao M, Wang M, Glick-Wilson BE, Meyer JA, Peters JS, Territo PR, et al. Synthesis and preliminary biological evaluation of a novel P2X7R radioligand [18F]IUR-1601. Bioorg Med Chem Lett. 2018;28(9):1603\u20139.","journal-title":"Bioorg Med Chem Lett"},{"issue":"9","key":"4369_CR30","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1016\/j.bmcl.2015.03.021","volume":"25","author":"M Gao","year":"2015","unstructured":"Gao M, Wang M, Green MA, Hutchins GD, Zheng QH. Synthesis of [11C]GSK1482160 as a new PET agent for targeting P2X(7) receptor. Bioorg Med Chem Lett. 2015;25(9):1965\u201370.","journal-title":"Bioorg Med Chem Lett"},{"key":"4369_CR31","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejphar.2017.12.006","volume":"820","author":"H Jin","year":"2018","unstructured":"Jin H, Han J, Resing D, Liu H, Yue X, Miller RL, et al. Synthesis and in vitro characterization of a P2X7 radioligand [123I]TZ6019 and its response to neuroinflammation in a mouse model of Alzheimer disease. Eur J Pharmacol. 2018;820:8\u201317.","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"4369_CR32","doi-asserted-by":"publisher","first-page":"458","DOI":"10.2967\/jnumed.116.181354","volume":"58","author":"PR Territo","year":"2017","unstructured":"Territo PR, Meyer JA, Peters JS, Riley AA, McCarthy BP, Gao M, et al. Characterization of 11C-GSK1482160 for targeting the P2X7 receptor as a biomarker for neuroinflammation. J Nucl Med. 2017;58(3):458\u201365.","journal-title":"J Nucl Med"},{"key":"4369_CR33","doi-asserted-by":"publisher","unstructured":"Tronel C, Largeau B, Santiago Ribeiro MJ, Guilloteau D, Dupont AC, Arlicot N. Molecular targets for PET imaging of activated microglia: the current situation and future expectations. Int J Mol Sci. 2017;18(4). \n                    https:\/\/doi.org\/10.3390\/ijms18040802\n                    \n                  .","DOI":"10.3390\/ijms18040802"},{"issue":"8","key":"4369_CR34","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s12149-016-1099-2","volume":"30","author":"T Terada","year":"2016","unstructured":"Terada T, Yokokura M, Yoshikawa E, Futatsubashi M, Kono S, Konishi T, et al. Extrastriatal spreading of microglial activation in Parkinson\u2019s disease: a positron emission tomography study. Ann Nucl Med. 2016;30(8):579\u201387.","journal-title":"Ann Nucl Med"},{"issue":"2","key":"4369_CR35","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.nbd.2005.08.002","volume":"21","author":"A Gerhard","year":"2006","unstructured":"Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson\u2019s disease. Neurobiol Dis. 2006;21(2):404\u201312.","journal-title":"Neurobiol Dis"},{"issue":"5","key":"4369_CR36","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.parkreldis.2013.01.017","volume":"19","author":"C Kobylecki","year":"2013","unstructured":"Kobylecki C, Counsell SJ, Cabanel N, Wachter T, Turkheimer FE, Eggert K, et al. Diffusion-weighted imaging and its relationship to microglial activation in parkinsonian syndromes. Parkinsonism Relat Disord. 2013;19(5):527\u201332.","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"4369_CR37","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/ana.20338","volume":"57","author":"Y Ouchi","year":"2005","unstructured":"Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T, et al. Microglial activation and dopamine terminal loss in early Parkinson\u2019s disease. Ann Neurol. 2005;57(2):168\u201375.","journal-title":"Ann Neurol"},{"issue":"Pt 9","key":"4369_CR38","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1093\/brain\/awv184","volume":"138","author":"A Jucaite","year":"2015","unstructured":"Jucaite A, Svenningsson P, Rinne JO, Cselenyi Z, Varnas K, Johnstrom P, et al. Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson\u2019s disease. Brain. 2015;138(Pt 9):2687\u2013700.","journal-title":"Brain"},{"issue":"1","key":"4369_CR39","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12974-016-0778-1","volume":"14","author":"C Ghadery","year":"2017","unstructured":"Ghadery C, Koshimori Y, Coakeley S, Harris M, Rusjan P, Kim J, et al. Microglial activation in Parkinson\u2019s disease using [18F]-FEPPA. J Neuroinflammation. 2017;14(1):8.","journal-title":"J Neuroinflammation"},{"issue":"9","key":"4369_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0138721","volume":"10","author":"Y Koshimori","year":"2015","unstructured":"Koshimori Y, Ko JH, Mizrahi R, Rusjan P, Mabrouk R, Jacobs MF, et al. Imaging striatal microglial activation in patients with Parkinson\u2019s disease. PLoS One. 2015;10(9):e0138721.","journal-title":"PLoS One"},{"issue":"1","key":"4369_CR41","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.parkreldis.2009.05.005","volume":"16","author":"AL Bartels","year":"2010","unstructured":"Bartels AL, Willemsen AT, Doorduin J, de Vries EF, Dierckx RA, Leenders KL. [11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson\u2019s disease? Parkinsonism Relat Disord. 2010;16(1):57\u20139.","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"4369_CR42","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S0987-7053(01)00273-8","volume":"31","author":"S Thobois","year":"2001","unstructured":"Thobois S, Guillouet S, Broussolle E. Contributions of PET and SPECT to the understanding of the pathophysiology of Parkinson\u2019s disease. Neurophysiol Clin. 2001;31(5):321\u201340.","journal-title":"Neurophysiol Clin"},{"issue":"4","key":"4369_CR43","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1136\/jnnp-2016-313918","volume":"88","author":"MJ Firbank","year":"2017","unstructured":"Firbank MJ, Yarnall AJ, Lawson RA, Duncan GW, Khoo TK, Petrides GS, et al. Cerebral glucose metabolism and cognition in newly diagnosed Parkinson\u2019s disease: ICICLE-PD study. J Neurol Neurosurg Psychiatry. 2017;88(4):310\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"4369_CR44","volume":"2012","author":"PF Durrenberger","year":"2012","unstructured":"Durrenberger PF, Grunblatt E, Fernando FS, Monoranu CM, Evans J, Riederer P, et al. Inflammatory pathways in Parkinson\u2019s disease; a BNE microarray study. Parkinsons Dis. 2012;2012:214714.","journal-title":"Parkinsons Dis"},{"issue":"3","key":"4369_CR45","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/bpa.12371","volume":"26","author":"S Lim","year":"2016","unstructured":"Lim S, Chun Y, Lee JS, Lee SJ. Neuroinflammation in synucleinopathies. Brain Pathol. 2016;26(3):404\u20139.","journal-title":"Brain Pathol"},{"issue":"1","key":"4369_CR46","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/mds.22732","volume":"25","author":"R Dodel","year":"2010","unstructured":"Dodel R, Spottke A, Gerhard A, Reuss A, Reinecker S, Schimke N, et al. Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [11C](R)-PK11195 PET (MEMSA-trial). Mov Disord. 2010;25(1):97\u2013107.","journal-title":"Mov Disord"},{"issue":"5","key":"4369_CR47","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1212\/01.WNL.0000078192.95645.E6","volume":"61","author":"A Gerhard","year":"2003","unstructured":"Gerhard A, Banati RB, Goerres GB, Cagnin A, Myers R, Gunn RN, et al. [11C](R)-PK11195 PET imaging of microglial activation in multiple system atrophy. Neurology. 2003;61(5):686\u20139.","journal-title":"Neurology"},{"issue":"1","key":"4369_CR48","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/mds.20668","volume":"21","author":"A Gerhard","year":"2006","unstructured":"Gerhard A, Trender-Gerhard I, Turkheimer F, Quinn NP, Bhatia KP, Brooks DJ. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in progressive supranuclear palsy. Mov Disord. 2006;21(1):89\u201393.","journal-title":"Mov Disord"},{"issue":"10","key":"4369_CR49","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1002\/mds.20162","volume":"19","author":"A Gerhard","year":"2004","unstructured":"Gerhard A, Watts J, Trender-Gerhard I, Turkheimer F, Banati RB, Bhatia K, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in corticobasal degeneration. Mov Disord. 2004;19(10):1221\u20136.","journal-title":"Mov Disord"},{"issue":"22","key":"4369_CR50","doi-asserted-by":"publisher","first-page":"e1989","DOI":"10.1212\/WNL.0000000000005610","volume":"90","author":"L Passamonti","year":"2018","unstructured":"Passamonti L, Rodriguez PV, Hong YT, Allinson KSJ, Bevan-Jones WR, Williamson D, et al. [11C]PK11195 binding in Alzheimer disease and progressive supranuclear palsy. Neurology. 2018;90(22):e1989\u2013e96.","journal-title":"Neurology"},{"issue":"14","key":"4369_CR51","doi-asserted-by":"publisher","first-page":"11135","DOI":"10.1074\/jbc.M010353200","volume":"276","author":"BJ Gu","year":"2001","unstructured":"Gu BJ, Zhang W, Worthington RA, Sluyter R, Dao-Ung P, Petrou S, et al. A Glu-496 to Ala polymorphism leads to loss of function of the human P2X7 receptor. J Biol Chem. 2001;276(14):11135\u201342.","journal-title":"J Biol Chem"},{"key":"4369_CR52","doi-asserted-by":"publisher","first-page":"36680","DOI":"10.1038\/srep36680","volume":"6","author":"B Kovanyi","year":"2016","unstructured":"Kovanyi B, Csolle C, Calovi S, Hanuska A, Kato E, Koles L, et al. The role of P2X7 receptors in a rodent PCP-induced schizophrenia model. Sci Rep. 2016;6:36680.","journal-title":"Sci Rep"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-019-04369-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-019-04369-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-019-04369-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T23:10:35Z","timestamp":1593040235000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-019-04369-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,26]]},"references-count":52,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["4369"],"URL":"https:\/\/doi.org\/10.1007\/s00259-019-04369-6","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,26]]},"assertion":[{"value":"24 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all individual participants prior to their inclusion in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}